Microglia Are the Hidden Cause of Sleep Loss in Alzheimer's

Imagine a sprinkler system that, in trying to douse a small kitchen fire, floods the whole house. The original threat is modest. The response makes matters worse. That image is what University of Kentucky scientists now use to describe a surprising driver of sleep loss in an Alzheimer's model: the brain's own immune cells.

Researchers led by Shannon L. Macauley and Nicholas J. Constantino traced how microglia, the brain's cellular sentinels, react to early amyloid deposits and in the process set off a neuroinflammatory cascade that keeps the brain awake. The work, published in Alzheimer's & Dementia, shifts attention away from plaques alone and toward the immune response rippling through the cortex.

They put tiny EEG and EMG headmounts on mice to read brain waves and muscle tone. Those measures let them separate wakefulness, NREM — the deep restorative sleep — and REM, the dreaming stage tied to memory. The team also cleared whole brains with light-sheet microscopy to map plaque and microglial activity in three dimensions. The data painted a clear picture: sleep disruption rose early, at the first sign of plaques, and then hit a ceiling even as plaques continued to accumulate.

Why did sleep hit that plateau? The answer came when the team gave the mice Pexidartinib (PLX3397), a drug known to deprive microglia of a critical survival signal. After two weeks, about 87% of microglia were temporarily gone. The result was startling. Removing most microglia restored more than two hours of sleep per day without reducing plaque levels. In short, the immune response, not plaque load per se, appeared to be the reversible culprit keeping the brain awake.

Short sentence. Punchy. Then more detail. The researchers used an analytical tool called FOOOF to parse rhythmic brain waves from background electrical 'noise' — the aperiodic signal. Think of it like checking whether an engine idles too high even when the car seems parked. In the Alzheimer's model, aspects of cortical EEG differed from normal aging. Aging was mainly linked to reduced REM sleep. Alzheimer-like pathology selectively eroded NREM, the stage most tied to waste clearance, metabolic repair, and memory consolidation.

That distinction matters. Losing NREM is not just losing sleep. It's losing the brain's nightly laundry service. Without it, toxins may linger and the brain could cascade toward more damage. Could restoring that sleep break a vicious cycle? The mice data say it might be possible.

These results also open practical doors. The team identified electrical patterns that differentiate Alzheimer-related disruption from ordinary aging. Portable EEG systems, already improving in comfort and affordability, could become practical screening tools that pick up early microglial-driven changes in sleep architecture. Imagine routine, home-based EEG monitoring that flags subtle shifts long before cognitive decline forces expensive, invasive testing.

Still, translation to humans is the hard part. Removing microglia wholesale is not a viable long-term therapy for people. So Macauley's lab is exploring gentler tactics: shifting microglial metabolism and reining in their inflammatory response instead of erasing the cells. Repurposed drugs under study include metformin and stiripentol, chosen for their effects on cellular fuel processing and neuronal excitability. The goal is to quiet the immune party without shutting down an essential component of brain health.

Science doesn't always follow a straight line. In this case, curiosity and a willingness to abandon assumptions led the team away from neurons and plaques as sole suspects, and toward a more complex immune story. Constantino and his colleagues emphasize that some of the most revealing experiments began when initial hypotheses failed. They followed the data. That approach revealed a mechanistic target for sleep restoration that could alter how clinicians think about early Alzheimer's interventions.

Questions remain. Will the same microglial behavior show up in humans? Can we tune microglia to preserve sleep without compromising their protective roles? And if we succeed in restoring NREM, will it slow cognitive decline? For now, the study offers proof of principle: the brain's immune system can drive sleep loss, and that process can be interrupted in a model organism. If quieting microglia can buy back lost hours of restorative sleep, it may also buy precious time for memory and cognition.